Literature DB >> 1582127

Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

P Airŏ1, S Braga, E Prati, D Brugnoni, M Bettinzioli, R Gorla, R Cattaneo.   

Abstract

Serum levels of the soluble form of the interleukin-2 receptor (sIL-2R) were measured in the sera of 32 patients with systemic lupus erythematosus. A significant correlation was observed between the levels of sIL-2R and the SLAM score of disease activity (R:0.40; p: less than 0.05). The correlation was slightly lower than those between the SLAM score and the levels of anti-dsDNA or of the complement activity. The levels of sIL-2R were not significantly correlated with those of serum anti-ds-DNA and complement, nor with a sign of peripheral blood B cell hyperactivity, such as the spontaneous in vitro production of anti-DNA antibodies.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1582127     DOI： 10.1007/bf02207093

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  20 in total

1.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  The soluble interleukin-2 receptor in rheumatic disease.

Authors:  L A Rubin
Journal:  Arthritis Rheum       Date:  1990-08

3.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

Review 4.  Measurement of systemic lupus erythematosus activity in clinical research.

Authors:  M H Liang; S A Socher; W N Roberts; J M Esdaile
Journal:  Arthritis Rheum       Date:  1988-07

5.  Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus.

Authors:  R M Blaese; J Grayson; A D Steinberg
Journal:  Am J Med       Date:  1980-09       Impact factor: 4.965

6.  Decreased number of peripheral blood CD4 + CD29+ lymphocytes and increased in vitro spontaneous production of anti-DNA antibodies in patients with active systemic lupus erythematosus.

Authors:  R Gorla; P Airò; F Franceschini; E Stefani; S Braga; A Tincani; R Cattaneo
Journal:  J Rheumatol       Date:  1990-08       Impact factor: 4.666

7.  Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation.

Authors:  D H Campen; D A Horwitz; F P Quismorio; G R Ehresmann; W J Martin
Journal:  Arthritis Rheum       Date:  1988-11

8.  Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Authors:  Y P Huang; L H Perrin; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

9.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

10.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422
View more
  2 in total

1.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

2.  Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus.

Authors:  W A Nockher; R Wigand; W Schoeppe; J E Scherberich
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.